Please login to the form below

Not currently logged in
Email:
Password:

LABA

This page shows the latest LABA news and features for those working in and with pharma, biotech and healthcare.

AZ prepares to file COPD triple, taking on rival GSK

AZ prepares to file COPD triple, taking on rival GSK

The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... triple –

Latest news

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    The results of the AERISTO trial are a blow to AZ’s ambitions for Bevespi (glycopyrronium/formoterol fumarate) – a long-acting muscarinic agonist (LAMA)/long-acting beta agonist (LABA) combination that ... The real battleground between the two

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol, LAMA 

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    moderate to severe COPD who are not adequately treated by the combination of an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA). ... The same indication was approved by the FDA in September, and makes Trelegy the first drug on the

  • With US approval, GSK now needs rapid uptake for COPD triple With US approval, GSK now needs rapid uptake for COPD triple

    The three-drug product delivers a long-acting beta agonist (LABA), a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid (ICS) from a single device, and is the first product

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    The new product adds long-acting muscarinic receptor antagonist (LAMA) umeclidinium to the ICS/LABA combination, which has proved so successful in GSK's big-selling Advair/Seretide (fluticasone propionate/salmeterol) ... The benefits of Trelegy/Elebrato -

More from news
Approximately 3 fully matching, plus 68 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).

  • Pharma deals during June 2013 Pharma deals during June 2013

    Currently in phase III clinical development for COPD, this combination of a long acting beta-2 agonist (LABA) and a long acting muscarinic antagonist (LAMA) is expected to become an important

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Raising Awareness: It’s World COPD Day today!

    If the patient’ s symptoms are not completely controlled with bronchodilators alone, ICS may be recommended in combination with a long-acting bronchodilator (LABA). ... If the patient has had exacerbations but is clinically stable then ICS can be

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics